Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant concern » significant economic (Expand Search)
concern decrease » content decreased (Expand Search)
Showing 681 - 700 results of 21,342 for search '(( significant decrease decrease ) OR ( significant concern decrease ))', query time: 0.56s Refine Results
  1. 681
    One-way ANCOVA results for Task 2. The bold values highlight statistically significant results of Task 2.

    One-way ANCOVA results for Task 2. The bold values highlight statistically significant results of Task 2. by Mucahit Gemici (21519313)

    Published 2025
    Save to List
    Saved in:
  2. 682
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 683
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 684
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 685
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 686
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 687
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 688
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 689
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 690
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 691
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 692
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 693
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 694
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 695
    Estimated average absolute and relative changes in energy (kcal/capita/day) from the no-policy counterfactual by phase, high-in status, and SES.

    Estimated average absolute and relative changes in energy (kcal/capita/day) from the no-policy counterfactual by phase, high-in status, and SES. by Lindsey Smith Taillie (3159258)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 696
    Weighted sociodemographic characteristics of the Kantar WorldPanel sample by year.

    Weighted sociodemographic characteristics of the Kantar WorldPanel sample by year. by Lindsey Smith Taillie (3159258)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 697
    Estimated average absolute and relative changes from the no-policy counterfactual by phase and high-in status.

    Estimated average absolute and relative changes from the no-policy counterfactual by phase and high-in status. by Lindsey Smith Taillie (3159258)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 698
    Mean observed, fitted, and counterfactual energy, saturated fat, sodium, and sugar per capita per day from high-in food and beverage purchases.

    Mean observed, fitted, and counterfactual energy, saturated fat, sodium, and sugar per capita per day from high-in food and beverage purchases. by Lindsey Smith Taillie (3159258)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 699
    Estimated average absolute and relative changes from the no-policy counterfactual by phase and beverage group.

    Estimated average absolute and relative changes from the no-policy counterfactual by phase and beverage group. by Lindsey Smith Taillie (3159258)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 700
    Mean observed, fitted, and counterfactual energy, saturated fat, sodium, and sugar per capita per day from total food and beverage purchases.

    Mean observed, fitted, and counterfactual energy, saturated fat, sodium, and sugar per capita per day from total food and beverage purchases. by Lindsey Smith Taillie (3159258)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: